Intravitreous Vascular Endothelial Growth Factor (VEGF) Inhibitor Therapy for Tamoxifen Induced Macular Edema

Bourla, Dan; Gonzales, Christine R.; Mango, Charles W.; Moral, Joel N.; Wirthlin, R.; Schwartz, Steven D.

doi:10.1080/08820530701418524

Cited by 12 publications

(3 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previous experience treating diffuse diabetic macular edema by inhibiting vascular endothelial growth factor, a potent inducer of vascular permeability, with intravitreal bevacizumab prompted us to initiate therapy for this patient. Bourla et al 6 reported improvement of tamoxifen-induced CME with intravitreal pegaptanib sodium (Macugen), but to our knowledge this is the first case of improved tamoxifenassociated crystalline maculopathy and resolved CME with intravitreal bevacizumab therapy.…”

Section: Report Of a Casementioning

confidence: 84%

Bevacizumab Therapy for Tamoxifen-Induced Crystalline Retinopathy and Severe Cystoid Macular Edema

Rahimy¹,

Sarraf²

2012

Arch Ophthalmol

View full text Add to dashboard Cite

Section: Report Of a Casementioning

confidence: 84%

Bevacizumab Therapy for Tamoxifen-Induced Crystalline Retinopathy and Severe Cystoid Macular Edema

Rahimy¹,

Sarraf²

2012

Arch Ophthalmol

View full text Add to dashboard Cite

“…Bourla and colleagues used intravitreal anti‐VEGF to treat tamoxifen‐induced macular oedema, providing improvement in visual acuity and decreased retinal thickness. The case reported by Bourla and colleagues as well as our experience treating diffuse diabetic macular oedema or macular oedema associated with age‐related macular degeneration with intravitreal ranibizumab, led us to try this therapeutic modality in our case. Of note, one month after ranibizumab injection, macular oedema had improved with an associated improvement in VA.…”

Section: Discussionmentioning

confidence: 99%

Macular oedema due to letrozole: A first case report

Moschos

Chatziralli

Zagouri

et al. 2012

Clinical and Experimental Optometry

View full text Add to dashboard Cite

A 72-year-old woman presented with unexplained, progressive, painless visual loss in the right eye during the past six months. At presentation visual acuity (VA) was 3/60 in the right eye and 6/6 in the left eye. Anterior segment examination and intraocular pressures were normal. Dilated fundoscopy revealed significant macular oedema in the right eye and a normal fundus appearance in the left eye. Her medical history was noteworthy for breast ductal carcinoma in situ, for which she had undergone right mastectomy three years earlier. She had not received chemotherapy or radiotherapy but she had been under treatment with letrozole 2.5 mg/day over the past three years. She did not receive any other medication.Optical coherence tomography showed intraretinal fluid and a significant increase in retinal thickness in the foveal and parafoveal areas, while fluorescein angiography detected foveal hyperfluorescence and leakage of the dye in the late phase. Multifocal electroretinogram showed a decreased response in both eyes. In suspicion of letrozolerelated retinopathy, the patient was advised to stop the medication. The patient agreed to receive an intravitreal injection of 0.05 ml/0.5 mg ranibizumab. One month later, VA in the right eye was 6/9 and macular oedema had apparently improved. This is the first reported case of letrozole-associated macular oedema treated with intravitreal ranibizumab.

show abstract

“…CME may be treated with intravitreal anti-VEGF, intravitreal corticosteroids, or oral carbonic anhydrase inhibitors. [465][466][467][468][469] The role of sulfasalazine in reducing the toxic effects of tamoxifen on the retina is still under investigation. 470…”

Section: Managementmentioning

confidence: 99%

The Impact of Systemic Medications on Retinal Function

Somisetty

Santina

Sarraf

et al. 2023

Asia-Pacific Journal of Ophthalmology

View full text Add to dashboard Cite

This study will provide a thorough review of systemic (and select intravitreal) medications, along with illicit drugs that are capable of causing various patterns of retinal toxicity. The diagnosis is established by taking a thorough medication and drug history, and then by pattern recognition of the clinical retinal changes and multimodal imaging features. Examples of all of these types of toxicity will be thoroughly reviewed, including agents that cause retinal pigment epithelial disruption (hydroxychloroquine, thioridazine, pentosan polysulfate sodium, dideoxyinosine), retinal vascular occlusion (quinine, oral contraceptives), cystoid macular edema/retinal edema (nicotinic acid, sulfa-containing medications, taxels, glitazones), crystalline deposition (tamoxifen, canthaxanthin, methoxyflurane), uveitis, miscellaneous, and subjective visual symptoms (digoxin, sildenafil). The impact of newer chemotherapeutics and immunotherapeutics (tyrosine kinase inhibitor, mitogen-activated protein kinase kinase, checkpoint, anaplastic lymphoma kinase, extracellular signal-regulated kinase inhibitors, and others), will also be thoroughly reviewed. The mechanism of action will be explored in detail when known. When applicable, preventive measures will be discussed, and treatment will be reviewed. Illicit drugs (cannabinoids, cocaine, heroin, methamphetamine, alkyl nitrite), will also be reviewed in terms of the potential impact on retinal function.

show abstract

Intravitreous Vascular Endothelial Growth Factor (VEGF) Inhibitor Therapy for Tamoxifen Induced Macular Edema

Abstract: A 59-year-old male patient with tamoxifen induced macular edema in both eyes was treated with intravitreous sodium pegaptanib. Follow-up clinical examination, OCT, and FA demonstrated reduced edema and leakage with improvement in visual acuity.

Cited by 12 publications

References 4 publications

Bevacizumab Therapy for Tamoxifen-Induced Crystalline Retinopathy and Severe Cystoid Macular Edema

Bevacizumab Therapy for Tamoxifen-Induced Crystalline Retinopathy and Severe Cystoid Macular Edema

Macular oedema due to letrozole: A first case report

The Impact of Systemic Medications on Retinal Function

Contact Info

Product

Resources

About